It was first launched in the U.S. as an immunomodulator for tumor immunotherapy. Now it has been clinically used in the treatment of many tumors. Research shows that the use of Thymosin a1 in tumor chemotherapy and radiotherapy can enhance patients' immunity, reduce toxic side effects and infection rate, improve patients' life quality, and increase remission rate and even survival rate. As a vaccine adjuvant, Thymosin a1 can enhance the immune response to viral vaccines such as influenza and hepatitis B vaccines for people with impaired or inhibited immune functions including patients who are receiving chronic hemodialysis and suffering from geriatric diseases.
According to the report, Thymosin a1 has been growing since it entered China, with its sales value increasing from less than CNY 7 million in 2015 to more than CNY 1.2 billion in 2017. The Chinese Thymosin a1 market is now dominated by the products of Patheon, Hainan Shuangcheng Pharmaceuticals Co., Ltd., Chengdu DIAO Jiuhong Pharmaceutical Factory, etc. By sales value, Patheon captured more than half of the market, becoming the most powerful market player in 2017. By sales volume, Chengdu DIAO Jiuhong Pharmaceutical Factory took up the largest market share. Many domestic enterprises seek to scrabble for market shares from Patheon by the advantage of low prices.
According to the researcher, the incidence of cancer is increasing with economic development, aggravating environmental pollution and residents' changing lifestyle. Therefore, the Thymosin a1 market will continue to grow from 2018 to 2022 as the immunomodulator market grows gradually.
Topics Covered:
- Size of Chinese Thymosin a1 market
- Competition pattern of the Chinese Thymosin a1 market
- Prices in the Chinese Thymosin a1 market
- Prospects of the Chinese Thymosin a1 market
Table of Contents
Companies Mentioned
- Patheon N.V.
- Chengdu DIAO Jiuhong Pharmaceutical Factory
- Hainan Shuangcheng Pharmaceuticals Co., Ltd.
- Hainan Zhonghe Pharmaceutical Co., Ltd.
- SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.
- Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.
- Chengdu Shengnuo Biopharm Co., Ltd.
- Harbin Pharmaceutical Group Bio-Engineering Co., Ltd.
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
